Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:25:57

ASTRO 2026 Debrief: Who Still Needs Hormone Therapy &...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/10/04

The Pharma Closeout's ASTRO 2026 Debrief covers the readouts from the American Society for Radiation Oncology meeting that matter for drug,diagnostic and payer strategy. Fourteen-year RTOG 0815 data re-open how much hormone therapy men need with prostate radiation, as Veracyte's Decipher andArtera compete to decide who can skip it. The NRG-GI003 plenary showed no survival improvement for protons over photons in liver cancer, Novocure's TRIDENT timing trial missed, and new data arrived on

en-us

00:08:47

Daily Roundup | Jaypirca Adds a First-Line CLL Choice...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/10/03

Delayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a trial against older chemotherapy guide today's treatment choice? Novartis agrees to $575 million upfront for Abogen's early-stage RNA medicine ABO2203, with closing still pending and autoimmune benefit unproven. Also: Pfizer's Litfulo (ritlecitinib) advances toward vitiligo filings; Biogen reports longer-term

en-us

00:08:35

Survodutide Phase 3 Comes With GI Tolerability Cost &...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/10/02

Boehringer's survodutide reached up to 13.1% weight loss in Phase 3 assuming patients stayed on treatment, but GI-related dropouts complicate its place in obesity and Type 2 diabetes. CMS's final GLOBE rule tests international prices in Medicare Part B rebates: what changes for patients and doctors? Regeneron's trevogrumab reduced lean-mass loss on scans with semaglutide, without proving greater strength. Also: Sanofi and Regeneron expand their Dupixent alliance with four long-acting antibodies;

en-us

00:11:34

Daily Roundup | Lilly's amylin add-on brings more...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/10/01

September 30 edition, released October 1. Date references in the audio are anchored to September 30.Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weight loss vs 14.8% for tirzepatide in a secondary Phase 2b comparison, while more patients stopped over adverse events. Rafael Holdings' Trappsol Cyclo missed its Phase 3 TRANSPORT-NPC goal in Niemann-Pick disease type C, yet a fourth-quarter filing is still planned. The daily roundup covers Roche's fenebrutinib Priority

en-us

00:14:21

Daily Roundup | uniQure's Mixed Huntington's Readout...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/30

September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongside a cancer-combination program, without acquiring Summit's drug rights. In the roundup: Veracyte's retrospective Decipher analysis in prostate cancer; FDA approval of Teva's Xgeva biosimilar; and Novo's license to Hengrui's early oral GLP-1/GIP program. Invivyd reports tolerability, not protection,

en-us

00:15:47

Daily Roundup| Mirum's Brelovitug Wins Phase 3 on Two...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/29

Mirum's brelovitug met Phase 3 AZURE-1's virus-plus-ALT endpoint on weekly and every-four-week dosing in chronic hepatitis delta; durable liver outcomes were not shown. Kodiak's Zenkuda and tabirafusp were noninferior to aflibercept 2 mg on vision in wet AMD, and 54% of Zenkuda patients reached a 24-week interval; neither was compared with newer alternatives. 4DMT started Phase 3 testing of 4D-150 in diabetic macular edema, while Roche will return emugrobart rights to Chugai after an obesity trial's

en-us

00:48:32

Full Week in Review | Gilead's Anito-cel, Genentech's...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/28

This full Week in Review is a comprehensive review of the week's covered stories across oncology, kidney and immune disease, respiratory disease, metabolic disease, neuroscience, rare disease and ophthalmology, plus financings, deals and five events ahead. Gilead's anito-cel gets its full peer-reviewed Phase 1 record before a December FDA target; myeloma groups define cure; and Genentech's Gazyva wins approval to reduce relapse risk in childhood-onset nephrotic syndrome. Also in the

en-us

00:12:08

Daily Roundup | Mirum Wins FOP Approval Despite...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/26

Mirum's Atebrioz (zilurgisertib) wins FDA approval for FOP despite a primary-endpoint miss; Carvykti (ciltacabtagene autoleucel) shows five-year disease control without maintenance in half of 20 myeloma patients. aTyr plans another efzofitimod trial in sarcoidosis. The roundup covers Pharming's Joenja (leniolisib), ADARx's IPO, Canada's Epkinly (epcoritamab) expansion, Novo–Nanexa's long-acting peptide deal, FDA nominee Heidi Overton's hearing, and Medicaid's GENEROUS

en-us

00:11:12

Daily Roundup| Merck–Eisai Win Kidney Cancer Approval...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/25

Welireg plus Lenvima gains FDA approval in advanced clear-cell kidney cancer, with better disease control but no demonstrated survival advantage. Lilly says FDA approved weekly insulin Onswik, entering a market where Novo’s Awiqli is already available. Merck’s remigromig meets its pivotal vision goal, but safety and dosing questions remain. Plus: Acadia advances after a Phase 2 miss; Kyverna reports autoimmune follow-up; Elevar gains bile-duct cancer approval; Takeda’s Adzynma gets a boxed warning;

en-us

00:13:11

GRAIL's Galleri Vote Puts Label and Coverage in Focus...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/24

GRAIL’s Galleri won backing from FDA advisers, but the narrow effectiveness split and a missed late-stage-cancer endpoint keep the label and coverage case in focus. Roche and Ionis report that sefaxersen reduced proteinuria in Phase 3 IgA nephropathy, while longer-term kidney-function data remain blinded and Novartis’s Fabhalta (iptacopan) sets the benchmark. Vertex tests inaxaplin in additional APOL1 kidney disease groups, and Amgen’s dazodalibep succeeds in systemic Sjögren’s disease. Plus:

en-us

00:12:35

Celldex Safety Clouds Pivotal Wins & Otsuka–Ionis ALS...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/23

Celldex's pivotal barzolvolimab wins in chronic hives carry an anaphylaxis signal. Otsuka and Ionis report a joint-endpoint ALS result for ulefnersen, while Iambic's IPO filing puts its AI platform and early cancer data before investors. Johnson & Johnson's Caplyta (lumateperone) reports bipolar mania data, Compass faces a filing-path question, and Roche's enicepatide and Viking's VK2735 add metabolic results. We also cover NewAmsterdam and Menarini's European obicetrapib

en-us

00:08:28

Beacon Gene Therapy Meets Pivotal Vision Endpoint &...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/22

Beacon’s pivotal VISTA trial met its endpoint in inherited vision loss, with low-light gains and surgical risks shaping the next questions. Telix’s $1.65 billion ITM deal combines isotope supply with an investigational cancer therapy facing manufacturing hurdles. Novo’s CagriSema result in diabetes, Cue’s chronic-hives data and Insmed’s ARIKAYCE (amikacin liposome inhalation suspension) review show different evidence and regulatory paths. FDA opens clearer routes for validated non-animal methods,

en-us

00:11:22

Week in Review | Novo’s Obesity Choices &...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/21

Novo adds obesity programs as its Ascendis collaboration ends, while ivonescimab's China survival results sharpen the test facing its global lung-cancer program. Europe moves Corcept's Lifyorli toward authorization and backs broader perioperative use of Padcev with Keytruda, while Bayer's Kerendia, Vera's Trutakna, Xenon's azetukalner and Vertex's pediatric cystic-fibrosis applications show different regulatory and evidence paths. Gilead's lenacapavir agreements separate preparation for an

en-us

00:09:11

Lilly Expands Breast Cancer Choices & Novo Signs for...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/19

FDA fully approved Lilly's Inluriyo (imlunestrant) plus Verzenio (abemaciclib) after progression in ESR1-mutated advanced breast cancer; evidence is exploratory in 159 patients versus Inluriyo alone, and overall survival remains immature. LEO says FDA accepted dersimelagon's filing with Priority Review—not approval—for light-sensitive EPP and XLP. Novo signed an asset purchase agreement for three Kallyope obesity programs and an Orbis cardiometabolic discovery pact; Electra priced an IPO,

en-us

00:12:24

Ultragenyx Wins Sanfilippo Type A Approval & Xenon...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/18

Ultragenyx's Fayuvi approval opens a first treatment path for eligible children with Sanfilippo syndrome type A, with preserved function and center access defining the boundary. Alex and Maya examine Xenon's azetukalner epilepsy filing and separate pause in new psychiatry enrollment, plus Roche's Phase 3 CELESTIMO endpoint result for Lunsumio in follicular lymphoma. They also cover Lisata's Marea acquisition and financing; Roche's Dualitas deal; Longeveron's laromestrocel

en-us

00:12:20

Skyhawk's Early Huntington Signal Faces a Bigger Test...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/17

Skyhawk's early SKY-0515 Huntington's signal faces randomized confirmation, while Sling's $123M financing advances oral linsitinib for thyroid eye disease. Alex and Maya examine Novartis's Sironax option and Cogent's bezuclastinib review timetable. They also cover FDA review patterns, Bausch + Lomb's warning letter, and Gilead and PAHO's lenacapavir access agreement. The briefing follows what these clinical, financial and regulatory developments mean, with the evidence

en-us

00:11:38

Vera's Kidney Data Strengthen the Case for Full FDA...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/16

Vera reports a 76% reduction in composite kidney-disease progression risk and near-stable two-year kidney function for TRUTAKNA (atacicept-vymj) in sponsor topline data, addressing the clinical-benefit question behind its accelerated approval in IgA nephropathy. Curium's BEXLUTRY (lutetium Lu 177 dotatate) brings an adult neuroendocrine-tumor competitor to Lutathera, with delivery and access questions still open. GSK buys a preclinical myeloma development bet, while Lilly backs nervous-system

en-us

00:11:33

Daily Roundup | Enhertu Delays Lung Cancer...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/15

Enhertu delayed lung cancer progression in a Phase 3 trial, but immature survival results and fatal lung toxicity complicate the first-line case. Definium reports a second Phase 3 anxiety-study win for DT120, while new ivonescimab results quantify a survival benefit previously announced. We also cover Sanofi's proposed Cheplapharm transaction, Cellectis's gene-editing pivot, Corbus's oral obesity candidate and regulatory updates from Amgen and Telix. This is the September 14 edition,

en-us

00:14:02

Week in Review | AstraZeneca’s Setback, Novartis...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/14

AstraZeneca's broader-use trial of Etcamah (camizestrant)missed its primary goal in advanced breast cancer, while the existing approval stands. Scholar Rock's ISEMBYLD (apitegromab) adds a muscle-directed option inspinal muscular atrophy, while Roivant's mosliciguat links vascular improvement with better walking distance in pulmonary hypertension associated with interstitial lung disease. Novartis faces pipeline and acquisition scrutiny asBiohaven pauses new BHV-7000 enrollment and

en-us

00:08:36

Exelixis Faces FDA Delay & Karyopharm Faces October...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/09/12

FDA extended its review of Exelixis's zanzalintinib-Tecentriq combination for metastatic colorectal cancer to March 3, 2027, after classifying updated data as a major amendment. Karyopharm missed a $15.8 million loan payment and secured a creditor standstill through October 15 tied partly to its selinexor-ruxolitinib myelofibrosis filing. Roche's Enspryng gained Priority Review in MOGAD; COSCIENS bought oral-film manufacturer Nualtis, and Frazier raised more than $1.1 billion for its Public Fund

en-us

169 results

Similar Podcasts

Beyond the Divide

Koala Moon

Planetterrian Daily

Patrick · Nerra Network

NSF’s Discovery Files Podcast

U.S. National Science Foundation

Curious City: Exploring Science and Wonders

Synthetic Universe

Science Busters Podcast

Martin Puntigam, Martin Moder, Florian...